Homocysteine: update on a new risk factor

Area of Science:

• Cardiovascular Medicine
• Clinical Biochemistry
• Nutritional Science

Background:

• Elevated fasting plasma homocysteine is a recognized independent risk factor for cardiovascular diseases, specifically atherosclerosis.
• Homocysteine also plays a role in the pathogenesis of venous thrombosis.
• Current evidence on the clinical efficacy of vitamin therapy to mitigate these risks remains inconclusive.

Purpose of the Study:

• To evaluate the impact of vitamin therapy on reducing homocysteine levels.
• To assess the clinical benefits and outcomes associated with lowering homocysteine through vitamin supplementation.
• To address the existing gap in evidence regarding the effectiveness of homocysteine-lowering therapies in preventing cardiovascular events and thrombosis.

Main Methods:

• Review of existing literature on homocysteine levels and cardiovascular risk.
• Analysis of studies investigating vitamin therapy interventions.
• Identification of ongoing clinical trials focusing on hard clinical endpoints.

Main Results:

• Vitamin therapy has demonstrated the ability to lower plasma homocysteine levels.
• However, a definitive benefit of this reduction on clinical outcomes such as atherosclerosis and venous thrombosis has not yet been established.
• Further research is warranted to confirm any potential therapeutic advantages.

Conclusions:

• While homocysteine-lowering via vitamin therapy is biochemically feasible, its clinical utility requires further validation.
• Ongoing studies are crucial for determining if reducing homocysteine levels translates into improved patient outcomes.
• The role of homocysteine as a modifiable risk factor needs continued investigation in large-scale clinical trials.